An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and…
Politics
·
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
CN
CitrixNews Staff
Originally reported by The Hill. Read the full story at the original source.
Related Articles
Politics
ICE detains San Diego Padres catching coordinator in El Paso
A minor-league catching coordinator for the San Diego Padres was detained by Immigration and Customs Enforcement (ICE) o...
CitrixNews Staff
·
58 minutes ago
Politics
Poll: 63 percent say inappropriate for Trump, family to profit from cryptocurrency
Most Americans believe it is inappropriate for President Trump to proft from cyrptocurrency while he is president, accor...
CitrixNews Staff
·
1 hour ago
Politics
Boston Globe endorses Moulton over incumbent Markey
The Boston Globe on Tuesday announced that it endorsed Rep. Seth Moulton (D-Mass.) in his Senate Democratic primary race...
CitrixNews Staff
·
1 hour ago
Politics
Almost 1 in 4 Trump voters see mass deportation campaign as too aggressive: Survey
Half of Americans say President Trump’s mass deportation is too aggressive, according to a new poll released Wednesday, ...
CitrixNews Staff
·
1 hour ago